The FDA issued its first approval for the use of A KRAS G12C inhibitor in a tumor type other than lung. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to adagrasib...
The FDA approved pembrolizumab, in combination with chemotherapy, for certain patients with endometrial cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) plus the chemotherapies carboplatin and paclitaxel, followed by pembrolizumab...
The FDA approved the bispecific T-cell engager blinatumomab for use in the consolidation phase of therapy for certain patients with leukemia. The U.S. Food and Drug Administration (FDA) has approved blinatumomab (Blincyto) for use...
The immunotherapy durvalumab may be used with chemotherapy to treat certain endometrial cancers. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) with chemotherapy, followed by durvalumab alone, for advanced or recurrent...
The targeted therapy Repotrectinib was approved for solid tumors with certain NTRK mutations, regardless of where the tumors originated. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib (Augtyro) for...
The RET inhibitor is now fully approved to treat certain patients with RET fusion-positive thyroid cancers. The U.S. Food and Drug Administration (FDA) has approved selpercatinib (Retevmo) for adults and children 2 years and...
The first-in-class targeted therapy inhibits telomerase, a cancer-promoting protein active in many cancers. The U.S. Food and Drug Administration (FDA) has approved imetelstat (Rytelo) for patients with low-risk or intermediate-1 risk myelodysplastic syndromes (MDS)...
The CAR T-cell therapy is now approved for some patients with relapsed/refractory mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with...
The FDA approved the RET inhibitor selpercatinib for children with thyroid cancer and other solid tumors harboring various RET alterations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to selpercatinib (Retevmo)...
Tarlatamab-dlle is the first bispecific T-cell engager approved to treat a solid tumor. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tarlatamab-dlle (Imdelltra) to treat patients with extensive-stage small cell lung...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now